Characterization of mesenchymal stem cells (MSCs) and their use in the treatment of COVID-19

Title : Characterization of mesenchymal stem cells (MSCs) and their use in the treatment of COVID-19

Abstract:

OUTLINE

• Discuss the history and properties of MSCs
• Discuss rationale for use of uMSC in COVID-19
• Present institutional Protocol for use of uMSC in COVID-19  pneumonia
• Present local experience and outcome of patients treated with  uMSC with COVID-19

Keywords: MSCs, uMSC, COVID-19, pneumonia.

Biography:

Dr. Vasiliki E. Kalodimou is the Assistant Professor as well as the former acting chair, at School of Medicine at the European University-Cyprus Ltd. Frankfurt Branch, Director at the Flow Cytometry-Research and Regenerative Medicine Department of IASO Maternity-Pediatric and Research Hospital in Athens, Greece, the Board/Committee on Research Ethics at the National Hellenic Research Foundation (Ε.Ι.Ε). Since 2006, Dr. Kalodimou has studied and working with stem cells from placenta, umbilical cord and adipose tissue, in every day practice and their applications in regenerative medicine, clinical trials, medical tourism and Flow Cytometry. Also, is working in the area of human genetics & population genetics as well as cellular standards. In addition to collaboration with state universities and pharmaceutical companies on research projects (20), Kalodimou frequently publishes (55 & 14 books/bestseller) her findings. She has 2 patents.